- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
Radiopharmaceutical Theragnostics Market is expected to reach US$ 3,441.97 million by 2028
Mar 27, 2023
Mediterranean Fish Vaccine Market is expected to reach US$ 2,09,030.80 million by 2030
Aug 10, 2023
Sanofi says COVID-19 vaccine will be available globally at the same time
May 15, 2020
Asia Pacific Transdermal Drug Delivery System Market is ready to achieve a Healthy CAGR during 2019-2027
Dec 04, 2020
Anti-Viral Therapies Market is expected to reach US$ 82,928.76 million in 2028
Jan 16, 2023
Moderna picks drugmaker Catalent to manufacture potential COVID-19 vaccine
Jun 25, 2020
Australia & South Korea Diabetic Foot Ulcer Market is expected to reach US$ 313.53 billion by 2030
Sep 20, 2023